ArticleTherapeutic innovation & regulatory science2026
Innovative Multidimensional Quantitative Benefit-Risk Model for Effective Decision Making in Research and Development for Biopharmaceutical Industry.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal products have benefits and risks that must be carefully balanced to inform decision making. The structured benefit-risk (BR) framework is a powerful approach not only to standardize a holistic BR assessment, but also to incorporate the patient perspective and guide the decisions and discussions of sponsors and regulatory agencies throughout the continuum of drug development. Structured BR assessment has been usually conducted using a qualitative approach during the late development stage. The use of quantitative models that can be applied throughout the drug development process may provide more objective BR information to support scientific recommendations to optimize and inform decisions for critical external and internal development opportunities. A new Multidimensional Benefit-Risk Integrated Evaluation (MBRIE) quantitative model was developed using key attributes of the structured BR assessment. Each attribute was evaluated by assigning a rating score ranging from 1 to 3 (low), 4-6 (medium), 7-10 (high). Also, two dimensions for comparative purposes were considered: standard of care (SOC) and probability of development success (PODS) (likelihood or favorability for development success). Graphical outputs were used to visualize and compare the ranking scores for each of the attributes across the two dimensions. This analysis implements a structured quantitative BR assessment approach earlier in drug development and through the drug lifecycle. The MBRIE model may be an innovative tool to facilitate solutions by fostering a collaborative culture that points to the true objective to improve patient outcomes.
Indexed as
Identifiers
41723330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.